Michael Burkes Brophy Sells 317 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 317 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $267.99, for a total transaction of $84,952.83. Following the completion of the sale, the chief financial officer directly owned 52,115 shares in the company, valued at $13,966,298.85. This trade represents a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Michael Burkes Brophy also recently made the following trade(s):

• On Tuesday, August 4th, Michael Burkes Brophy sold 478 shares of Natera stock. The stock was sold at an average price of $274.22, for a total transaction of $131,077.16.
• On Wednesday, July 29th, Michael Burkes Brophy sold 1,863 shares of Natera stock. The stock was sold at an average price of $249.38, for a total transaction of $464,594.94.
• On Tuesday, July 28th, Michael Burkes Brophy sold 2,419 shares of Natera stock. The shares were sold at an average price of $253.96, for a total transaction of $614,329.24.
• On Monday, July 27th, Michael Burkes Brophy sold 782 shares of Natera stock. The shares were sold at an average price of $260.49, for a total value of $203,703.18.

Natera Stock Down 0.2%

NASDAQ:NTRA traded down $0.61 during trading hours on Wednesday, reaching $274.58. 1,128,660 shares of the stock were exchanged, compared to its average volume of 1,104,859. The business has a 50-day moving average of $251.03 and a two-hundred day moving average of $222.85. Natera, Inc. has a twelve month low of $135.75 and a twelve month high of $288.04. The company has a market capitalization of $39.32 billion, a price-to-earnings ratio of -168.45 and a beta of 1.51.

Hedge Funds Weigh In On Natera

Several hedge funds and other institutional investors have recently made changes to their positions in NTRA. Elevation Wealth Partners LLC acquired a new position in shares of Natera during the second quarter worth about $30,000. Reflection Asset Management purchased a new position in Natera in the fourth quarter worth approximately $29,000. Palladiem LLC purchased a new position in Natera in the fourth quarter worth approximately $31,000. Bank of Jackson Hole Trust grew its holdings in Natera by 103.8% during the 4th quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock worth $37,000 after acquiring an additional 83 shares in the last quarter. Finally, International Assets Investment Management LLC grew its holdings in Natera by 132.9% during the 1st quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock worth $35,000 after acquiring an additional 97 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Wall Street Analysts Forecast Growth

NTRA has been the topic of several research reports. Royal Bank Of Canada assumed coverage on Natera in a research note on Thursday, June 11th. They set an “outperform” rating and a $275.00 target price on the stock. Barclays dropped their target price on Natera from $280.00 to $260.00 and set an “overweight” rating for the company in a research report on Wednesday, June 24th. TD Cowen reiterated a “buy” rating on shares of Natera in a research note on Wednesday, July 15th. Canaccord Genuity Group increased their price target on shares of Natera from $285.00 to $330.00 and gave the stock a “buy” rating in a research report on Tuesday, July 14th. Finally, JPMorgan Chase & Co. upped their target price on shares of Natera from $260.00 to $265.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Natera has an average rating of “Moderate Buy” and a consensus price target of $267.83.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.